CEO Fred Aslan (Artiva)
NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal
Not even one month after Big Pharma took notice of Artiva when Merck signed a collaboration worth nearly $2 billion in milestones, the off …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
